Ausgabe 1/2017
Inhalt (20 Artikel)
Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis
Rajiv P. Parikh, Elizabeth B. Odom, Liyang Yu, Graham A. Colditz, Terence M. Myckatyn
A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy
Jacques Raphael, Thivaher Paramsothy, Nim Li, Justin Lee, Sonal Gandhi
Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer
Joe Yeong, Aye Aye Thike, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Siew-Cheng Wong, Susan Swee Shan Hue, Puay Hoon Tan, Jabed Iqbal
Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease
Ashok Chakraborty, Christos Hatzis, Michael P. DiGiovanna
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Amila Orucevic, John L. Bell, Alison P. McNabb, Robert E. Heidel
The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer
J. S. Thomas, A. M. Hanby, N. Russell, G. van Tienhoven, K. Riddle, N. Anderson, D. A. Cameron, J. M. S. Bartlett, T. Piper, C. Cunningham, P. Canney, I. H. Kunkler
The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer
Ki-Tae Hwang, Young A. Kim, Jongjin Kim, A. Jung Chu, Ji Hyun Chang, So Won Oh, Kyu Ri Hwang, Young Jun Chai
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
Briete Goorts, Thiemo J. A. van Nijnatten, Linda de Munck, Martine Moossdorff, Esther M. Heuts, Maaike de Boer, Marc B. I. Lobbes, Marjolein L. Smidt
Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer
Linda Zetterlund, Fuat Celebioglu, Rimma Axelsson, Jana de Boniface, Jan Frisell
Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer
Linda Holmstrand Zetterlund, Jan Frisell, Athanasios Zouzos, Rimma Axelsson, Thomas Hatschek, Jana de Boniface, Fuat Celebioglu
Management of small T1a/b breast cancer by tumor subtype
Tanja Ignatov, Holm Eggemann, Elke Burger, Serban Dan Costa, Atanas Ignatov
Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology
EC Inwald, O Ortmann, M Koller, F Zeman, F Hofstädter, M Evert, G Brockhoff, M Klinkhammer-Schalke
A polygenic risk score for breast cancer risk in a Taiwanese population
Yi-Chen Hsieh, Shih-Hsin Tu, Chien-Tien Su, Er-Chieh Cho, Chih-Hsiung Wu, Mao-Chih Hsieh, Shiyng-Yu Lin, Yun-Ru Liu, Chin-Sheng Hung, Hung-Yi Chiou
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients
Boyoung Park, Ji Yeon Sohn, Kyong-Ah Yoon, Keun Seok Lee, Eun Hae Cho, Myong Cheol Lim, Moon Jung Yang, Soo Jin Park, Moo Hyun Lee, See youn Lee, Yoon Jung Chang, Dong Ock Lee, Sun-Young Kong, Eun Sook Lee
Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities
Carol A. Parise, Vincent Caggiano
Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases
T. J. A. van Nijnatten, J. M. Simons, M. Moossdorff, L. de Munck, M. B. I. Lobbes, C. C. van der Pol, L. B. Koppert, E. J. T. Luiten, M. L. Smidt
Oncologist and organizational factors associated with variation in breast cancer multigene testing
Tracy A. Lieu, G. Thomas Ray, Stephanie R. Prausnitz, Laurel A. Habel, Stacey Alexeeff, Yan Li, Scott D. Ramsey, Charles E. Phelps, Neetu Chawla, Suzanne C. O’Neill, Jeanne S. Mandelblatt
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
Synnøve Yndestad, Eilin Austreid, Stian Knappskog, Ranjan Chrisanthar, Peer Kåre Lilleng, Per Eystein Lønning, Hans Petter Eikesdal
Retrospective review of genomic testing in breast cancer: Does it improve outcome?
Grady M. Gastelum, Cyrus Iqbal, Susan G. Hilsenbeck, Mothaffar F. Rimawi, Polly Niravath
Erratum to: Diagnostic performance of tomosynthesis and breast ultrasonography in women with dense breasts: a prospective comparison study
Won Hwa Kim, Jung Min Chang, Joongyub Lee, A Jung Chu, Mirinae Seo, Hye Mi Gweon, Hye Ryoung Koo, Su Hyun Lee, Nariya Cho, Min Sun Bae, Sung Ui Shin, Sung Eun Song, Woo Kyung Moon